NASDAQ:AMGNAmgen Stock Price, Forecast & News

Amgen's stock was trading at $198.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMGN shares have increased by 27.4% and is now trading at $253.15. View which stocks have been most impacted by Coronavirus.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 11 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amgen.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Amgen.

Amgen, Inc. (NASDAQ:AMGN) posted its quarterly earnings data on Thursday, April, 30th. The medical research company reported $4.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.70 by $0.47. The medical research company had revenue of $6.16 billion for the quarter, compared to analyst estimates of $6.01 billion. Amgen had a net margin of 32.03% and a return on equity of 90.75%. The business's quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the company posted $3.56 EPS. View Amgen's earnings history.

Amgen declared a quarterly dividend on Wednesday, March 4th. Shareholders of record on Monday, May 18th will be given a dividend of $1.60 per share on Monday, June 8th. This represents a $6.40 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend is Friday, May 15th. View Amgen's dividend history.

Amgen issued an update on its FY20 earnings guidance on Thursday, April, 30th. The company provided earnings per share (EPS) guidance of $14.85-15.60 for the period, compared to the Thomson Reuters consensus estimate of $15.34. The company issued revenue guidance of $25.0-25.6 billion, compared to the consensus revenue estimate of $25.21 billion.

28 equities research analysts have issued 12 month target prices for Amgen's shares. Their forecasts range from $185.00 to $291.00. On average, they anticipate Amgen's share price to reach $246.08 in the next twelve months. This suggests that the stock has a possible downside of 2.8%. View analysts' price targets for Amgen.

Headlines about AMGN stock have been trending negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amgen earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Amgen.

Some companies that are related to Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD) and AbbVie (ABBV).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by many different institutional and retail investors. Top institutional investors include Cullinan Associates Inc. (0.03%), State of Alaska Department of Revenue (0.02%), Courier Capital LLC (0.01%), American National Bank (0.01%), Martin Capital Partners LLC (0.00%) and Burns J W & Co. Inc. NY (0.00%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank, Municipal Employees Retirement System of Michigan, Nelson Van Denburg & Campbell Wealth Management Group LLC, OmniStar Financial Group Inc., M&R Capital Management Inc., Gantzert Investment Co. LLC ADV, Martin Capital Partners LLC, and Courier Capital LLC. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar. View insider buying and selling activity for Amgen.

AMGN stock was bought by a variety of institutional investors in the last quarter, including Cullinan Associates Inc., State of Alaska Department of Revenue, Renaissance Investment Group LLC, American National Bank, Wiley BROS. Aintree Capital LLC, Legacy Capital Partners Inc., Ellenbecker Investment Group, and Summit Financial Group Inc.. View insider buying and selling activity for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $253.15.

Amgen has a market capitalization of $148.91 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

The official website for Amgen is www.amgen.com.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]